Landos Biopharma Raises $10 Million in Series A Financing

First company Launched Under Xontogeny Accelerator Model; Chris
Garabedian Joins Landos Board to Provide Strategic and Operating

Perceptive Advisors Will Serve as Exclusive Investor

Biopharma, Inc.
, an emerging biopharmaceutical company focused on
developing improved treatments for autoimmune diseases, announced today
it has raised $10 million in a Series A financing led by life sciences
investment management firm Perceptive
Advisors, LLC
, which will serve as its exclusive investor for the
Series A round.

Landos, founded by serial entrepreneur and innovator Dr. Josep
Bassaganya-Riera, is advancing a robust pharmaceutical pipeline for
autoimmune diseases toward commercialization and will partner
operational efforts with Xontogeny,
, a life sciences accelerator operating company led by industry
veteran Chris Garabedian. Xontogeny’s model works in synergy with
partner companies to support management teams and provide expertise and
strategic direction in the early stages of pharmaceutical and
biotechnology development.

Current therapies for autoimmune diseases, a $100 billion market, have
limited efficacy and significant side effects. Landos’ mission is to
accelerate the development of safer, more effective therapeutics for
painful and debilitating autoimmune diseases including Crohn’s disease
and ulcerative colitis.

“I’m thrilled to have Xontogeny and Chris Garabedian as a strategic and
operating partner along with Perceptive Advisors as Landos’ exclusive
financier in the Series A, to bring our lead product, BT-11, through
initial clinical studies in 2018,” said Landos Chairman and CEO, Dr.
Josep Bassaganya-Riera “We have a committed leadership team with
industry experience focused on developing oral treatments that address
an unmet clinical need of patients, can disrupt the $9.2 billion per
year inflammatory bowel disease (IBD) therapeutics market, and most
importantly improve the lives of millions of patients living with these

Landos will focus its development efforts in a novel target pathway
called Lanthionine Synthetase C-Like 2 (LANCL2), which has shown
promise for the treatment of autoimmune diseases by engaging a unique
mechanism of action that exerts potent anti-inflammatory effects.
Landos’ lead product candidate BT-11 is a first-in-class, orally active,
locally-acting therapeutic for treatment of Crohn’s disease and
ulcerative colitis that has shown a benign safety profile in animal
models and that is advancing toward an Investigational New Drug (IND)
filing. BT-11 intercepts IBD by decreasing the production of
inflammatory mediators and increasing anti-inflammatory molecules within
the gastrointestinal tract. IBD impacts approximately 1.6 million
Americans and 4 million people worldwide.

“Landos is an exciting company for Xontogeny to partner with as Josep
and his team have produced very compelling data in animal models of IBD
and have brought their lead compound, BT-11, to the cusp of clinical
trials,” said Mr. Garabedian, who will serve as a Landos Board member
and senior business advisor. “The properties of BT-11 are unique and
well differentiated from current IBD products and we believe it has the
potential to represent an advance in the treatment of both Crohn’s
disease and ulcerative colitis.”

“We are extremely excited to partner with both Josep and Chris to build
Landos into a global biopharmaceutical company focused on autoimmune
diseases, and are convinced that the team will provide an accelerated
path to compelling clinical proof-of concept for IBD,” said Joe Edelman,
CEO of Perceptive Advisors. “As the first investment in a Xontogeny
portfolio company since partnering with Chris earlier this year, we
believe that Landos exemplifies the company profile we aim to support –
an outstanding leadership team, a lead product with a novel mechanism,
strong IP, and a compelling preclinical and translational dataset that
is close to the clinic for the treatment of an important disease with an
unmet need for safer and more effective drugs.”

With the Series A investment, Landos plans to complete remaining
IND-enabling studies, file an IND for BT-11 in 2018 and expects to
complete Phase 1 clinical testing by early 2019.

For more information about Landos Biopharma, visit
For more information about Xontogeny, visit
For more information about Perceptive Advisors, visit

About Landos Biopharma, Inc.

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused
on the discovery and development of first-in-class oral therapeutics for
patients with autoimmune diseases. Landos’ lead clinical asset, BT-11,
is a novel, locally-acting small molecule targeting inflammatory bowel
disease (IBD) that is expected to enter clinical testing for Crohn’s
disease in 2018. Landos also has a robust pipeline of compounds for
other autoimmune diseases. Landos is headquartered in Blacksburg, VA.
For more information, please visit,
or follow the company on Twitter at @LandosBio.

About Xontogeny, LLC

Based in Boston, MA, Xontogeny
seeks to accelerate the development of life science technologies by
providing entrepreneurs with the leadership, strategic guidance and
operational support necessary to increase the probability of success in
early drug and technology development. Through a differentiated
approach, the Xontogeny team partners with the founding scientists and
entrepreneurs of new ventures to support their vision while allowing a
more efficient development model to benefit company founders and early
equity holders. For more information, please visit
or contact Xontogeny by emailing

About Perceptive Advisors

Founded in 1999 and based in New York, NY, Perceptive Advisors is an
investment management firm focused on supporting the progress of the
life sciences industry by identifying opportunities and directing
financial resources to the most promising technologies in healthcare.
For more information about Perceptive, visit


Company Contacts:
Landos Biopharma:
Sandstead, 540-218-2232
Petty, 857-241-3704
Media Requests:

Andrew Mastrangelo
Science, 617-374-8800, ext. 108